155802-08-7

Basic information

• Product Name: 1,3,5-Trihexyl-2,4,6-triiodobenzene
• CAS NO: 155802-08-7
• Molecular Formula: C₂₄H₃₉I₃
• Molecular Weight: 708.29163
• Mol File: 155802-08-7.mol

Chemical Properties

• CAS DataBase Reference: 1,3,5-Trihexyl-2,4,6-triiodobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,5-Trihexyl-2,4,6-triiodobenzene(155802-08-7)
• EPA Substance Registry System: 1,3,5-Trihexyl-2,4,6-triiodobenzene(155802-08-7)

Safety Data

• Hazardous Substances Data: 155802-08-7(Hazardous Substances Data)

Upstream product

• 111-25-1 1-bromo-hexane 
• 29536-28-5 1,3,5-trihexylbenzene 
• 2712-78-9 bis-[(trifluoroacetoxy)iodo]benzene 
• 108-70-3 1,3,5-trichlorobenzene 

Relevant articles and documents

A shape-persistent organic molecular cage with high selectivity for the adsorption of CO2 over N2

Carbon capture in an organic cage: A shape-persistent, organic prismatic molecular cage (see structure) was synthesized in one step and high yield from readily accessible starting materials through dynamic covalent chemistry. The resulting cage molecule exhibited high selectivity for the adsorption of CO2 over N2 and thus shows promise as a carbon-capture material. Copyright

1,3,5-Trialkyl-2,4,6-triiodobenzenes: Novel x-ray contrast agents for gastrointestinal imaging

Examination of the gastrointestinal (GI) tract has been performed for decades using barium sulfate. Although this agent has many recognized limitations including extreme radiopacity, poor intrinsic affinity for the GI mucosa, and very high density, no alternative contrast agents have emerged which produce comparable or better contrast visualization. In fact, the various techniques of the GI radiologic examination (i.e., single contrast, double contrast, biphasic) were developed to compensate for its limitations. Each of these techniques requires complex patient manipulation to achieve adequate mucosal coating or compression to overcome the marked radiopacity of barium sulfate in order to obtain a diagnostically useful examination. A series of novel radiopaque oils, the 1,3,5-trialkyl-2,4,6-triiodobenzenes, was designed to improve the efficacy, stability, and safety of barium formulations. These substances were prepared in two steps from 1,3,5- trichlorobenzene. Compound 17 (1,3,5-tri-n-hexyl-2,4,6-triiodobenzene), formulated as an oil-in-water emulsion, was found to be well-tolerated in rodents (mice, hamsters, rats) following acute oral and/or intraperitoneal administrations at 4 times the anticipated human clinical dose. No metabolism of 17 was detected in rat, hamster, dog, monkey, or human hepatic microsomes, suggesting the lack of oral toxicity was a consequence of poor absorption. In imaging experiments in dogs, emulsions of 17 have demonstrated excellent mucosal coating and improved radiodensity relative to barium sulfate suspensions. On the basis of the preliminary imaging and toxicity data, compound 17 was selected as a potential development candidate.

Compositions of alkylbenzenes and cellulose derivatives for visualization of the gastrointestinal tract

Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising an x-ray producing agent of the formula or a pharmaceutically acceptable salt thereof STR1 wherein R is methyl, ethyl, n-propyl, C4 -C25 alkyl, cycloalkyl, unsaturated allyl or halo-lower-alkyl, each of which may be optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy or lower-alkoxy carbonyl; (CR1 R2)p --(CR3 =CR4)m Q, or (CR1 R2)p --C C--Q; R1, R2, R3 and R4 are independently H, lower-alkyl, optionally substituted with halo; n is 2-5; m is 2-5; p is 1-10; and Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl; in a pharmaceutically acceptable carrier comprising a cellulose derivative.

Compositions of alkylbenzenes for visualization of the gastrointestinal tract using X-ray contrast

Disclosed are contrast agents of the formula STR1 contained in aqueous compositions and methods for their use in diagnostic radiology of the gastrointestinal tract wherein R=C1 -C25 alkyl, cycloalkyl, unsaturated allyl or halo-lower-alkyl, optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy, lower-alkoxy carbonyl or lower-alkoxy-carbonyloxy, (CR1 R2)p --(CR3 =CR4)m Q, or (CR1 R2)p --C C--Q; R1, R2, R3 and R4 are independently H, lower-alkyl, optionally substituted with halo; n is 1-5; m is 1-5; p is 1-10; and Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl.

Compositions of alkylbenzenes in film-forming materials for visualization of the gastrointestinal tract

Disclosed are x-ray contrast compositions for oral or retrograde examination of the gastrointestinal tract comprising a polymeric material capable of forming a coating on the gastrointestinal tract and an x-ray producing agent of the formula STR1 and methods for their use in diagnostic radiology of the gastrointestinal tract wherein R=C1 -C25 alkyl, cycloalkyl, unsaturated allyl or halo-lower-alkyl, optionally substituted with halo, fluoro-lower-alkyl, aryl, lower-alkoxy, hydroxy, carboxy, lower-alkoxy carbonyl or lower-alkoxy-carbonyloxy, (CR1 R2)p --(CR3 =CR4)m Q, or (CR1 R2)p --C C--Q; R1, R2, R3 and R4 are independently H, lower-alkyl, optionally substituted with halo; n is 1-5; m is 1-5; p is 1-10; and Q is H, lower-alkyl, lower-alkenyl, lower-alkynyl, lower-alkylene, aryl, or aryl-lower alkyl.